Wanneer gaan we patiënten een ‘polypil’ geven?

Translated title of the contribution: When will we treat patients with a polypill shortly after myocardial infarction?

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The 'polypill' stands for fixed-dosed combination pills with generic drugs that act on multiple cardiovascular risk factors. Data from randomized controlled trials show consistent beneficial effects of treatment with a polypill on both cardiovascular risk factors and relevant marjor cardiovascular endpoints. However, polypills are not readily available worldwide and only a limited number of polypills is marketed in Europe. Physicians have to embrace polypills in regular care to let the patient benefit from the advantages of the polypill. Licensing more polypills is an essential step to implement these pills in clinical care. Regulatory agencies need to reduce the dossier content requirements for registrations of new fixed-dosed combination pills so generic pharmaceutical companies can expand the number of marketed polypills.

Translated title of the contributionWhen will we treat patients with a polypill shortly after myocardial infarction?
Original languageDutch
Article numberD7377
JournalNederlands Tijdschrift voor Geneeskunde
Volume167
Publication statusPublished - 11 Apr 2023

Fingerprint

Dive into the research topics of 'When will we treat patients with a polypill shortly after myocardial infarction?'. Together they form a unique fingerprint.

Cite this